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Abstract
Background: Neuropathological data and nuclear medicine imaging show extensive serotonergic impairment in
Parkinson’s disease (PD). We undertook a case-controlled analysis of 123I-FP-CIT SPECT images to measure
extrastriatal serotonergic transporters (SERT) in PD using the Parkinson’s Progression Markers Initiative (PPMI) cohort.
Methods: We included all PD (n = 154) and Control subjects (n = 62) with available 123I-FP-CIT SPECT imaging and
high-resolution T1-weighted MRI for coregistration (PD: mean age 61.6 years, 62% male, disease duration 26 months,
MDS-UPDRS III score 22). 123I-FP-CIT SPECT images were processed with PETPVE12 using an exploratory voxel-wise
analysis including partial-volume effect correction. Linear regressions were performed in the PD group to assess
correlations between region of interest 123I-FP-CIT uptake and clinical motor and non-motor impairment.
Results: Compared to Controls, PD exhibited an uptake reduction in bilateral caudate nucleus, putamen, insula,
amygdala and right pallidum (family-wise error (FWE)-corrected p < 0.05). While lower putaminal uptake on the
contralateral side to clinically more affected side was associated with higher MDS-UPDRS III score (p = 0.022), we
found a trend association between higher geriatric depression scale and lower pallidum uptake (p = 0.09). Higher
SCOPA-AUT gastrointestinal subscore was associated with lower uptake in mean putamen and caudate nucleus
(p = 0.01 to 0.03), whereas urological subscore was inversely correlated with mean caudate nucleus, putamen, and
pallidum uptake (p = 0.002 to 0.03). REM sleep behaviour disorder screening questionnaire was associated with
lower 123I-FP-CIT binding in caudate nucleus, putamen and pallidum (all p < 0.05). No significant association was
found for Montreal Cognitive Assessment (all p > 0.45) or excessive daytime sleepiness (all p > 0.29).
Conclusions: In addition to the well-established striatal deficit, this study provides evidence of a major extrastriatal
123I-FP-CIT impairment, and therefore of an altered serotonergic transmission in early PD.
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Background
123I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophe-
nyl) nortropane (123I-FP-CIT) is the most widely used
single photon emission computed tomography (SPECT)
ligand to assess the integrity of presynaptic nigrostriatal
pathways [1]. Thus far, little attention has been paid to
extrastriatal binding of 123I-FP-CIT which mainly (70%)
derives from serotonergic transporters (SERT) density
[2]. Serotonin (5-hydroxy-tryptamine, 5-HT) regulates
many higher brain functions including cognition, mood
and motor behaviour – all being impaired in degenera-
tive parkinsonisms. 5-HT is synthesized in the raphe nu-
clei of the brainstem which project rostrally to the
cortex, thalamus and basal ganglia and caudally to the
spinal cord [3]. Evidence from post-mortem and in vivo
11C-3-amino-4-(2-dimethylaminomethyl-phenylsulfanyl)
benzonitrile (11C-DASB) positron emission tomography
(PET) imaging has demonstrated serotonergic cell loss
in degenerative forms of parkinsonism, especially in
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Parkinson’s disease (PD) and Progressive Supranuclear
Palsy (PSP) [4–6]. 123I-FP-CIT SERT concentration has
been shown to be higher in females and to decline with
age [7], and reduced uptake has been observed for PD in
frontal areas, thalamus, amygdala and insula [8, 9], con-
firming 11C-DASB PET findings.
Using the Parkinson’s Progression Markers Initiative
(PPMI) database [10], we here propose a case-controlled
extrastriatal 123I-FP-CIT assessment of early PD subjects. In
addition, we performed correlation analyses of striatal and
extrastriatal significant regions of interest (ROI) uptake
with clinical motor and non-motor scales, i.e. Movement
Disorders Society (MDS)-Unified Parkinson’s Disease
Rating Scale (UPDRS) part III at baseline and at 1-
year follow-up [11], Geriatric Depression Scale (GDS)
[12], Montreal Cognitive Assessment (MoCA) [13],
SCale for Outcome in PArkinson’s disease – AUTo-
nomic dysfunction (SCOPA-AUT) [14], Epworth
Sleepiness Scale (ESS) [15] and REM-sleep behaviour
screening questionnaire (RBDSQ) [16].
Methods
Participants
As of 4th February 2019, 423 PD and 196 Controls
(CTL) were enrolled in the PPMI study. For the present
work, we included all subjects who had both 123I-FP-CIT
SPECT imaging and high-resolution 3 T T1-weighted
magnetization-prepared rapid gradient echo (MPRAGE)
MRI performed within 3months. In addition, inclusion
was limited to individuals aged over 40 years to ensure
that only sporadic rather than genetic cases were taken
into consideration. We also collected clinical data from
the PPMI database, i.e. total scores of the MDS-UPDRS
III scale (off-state, ≥6 h after dopaminergic treatment dis-
continuation) at baseline (within 3 months of scans) and
at 1-year follow-up, as well as Hoehn and Yahr stage [17].
Non-motor impairment at baseline was assessed using
measures of cognition (MoCA) [13], depression (GDS)
[12], dysautonomia with SCOPA-AUT scale [14], includ-
ing gastrointestinal (SCOPA-GI, 7 items) and urinary
(SCOPA-URO, 6 items) subscores, as well as excessive
daytime sleepiness (ESS) [15] and REM-sleep behaviour
disorder (RBDSQ) [16].
MRI imaging
All patients were scanned on a 3 T Siemens Magnetom
TRIO Tim MRI scanner (Siemens Medical Solutions,
Erlangen, Germany) using a 32-channel head coil.
MPRAGE structural T1-weighted images were ac-
quired with the following parameters: TR = 2300 ms,
TE = 3 ms, flip angle = 9°, 256x256x240 mm matrix
and voxel size = 1 mm3 (isotropic).
SPECT imaging acquisition, reconstruction and
preprocessing
Reconstructed and attenuation-corrected 123I-FP-CIT
SPECT imaging data was downloaded from the PPMI
website. Images were acquired on a Siemens or General
Electric SPECT tomographs, 3-4 h after 123I-FP-CIT injec-
tion. The imaging protocol for the PPMI scans is docu-
mented in http://www.ppmi-info.org/wp-content/uploads/2
013/02/PPMI-Protocol-AM5-Final-27Nov2012v6-2.pdf.
Preprocessing of SPECT brain images was performed
using Statistical Parametric Mapping (SPM12, Wellcome
Trust Centre for Neuroimaging, London, UK, https://
www.fil.ion.ucl.ac.uk/spm/), running in MATLAB R2018b
Version 9.5.0 (MathWorks Inc., Sherborn, MA, USA).
SPECT images were coregistered to each patient’s own
MPRAGE structural MRI, partial-volume-effect-corrected
with the PETPVE12 toolbox running on SPM [18] after
segmenting the MRI into grey matter, white matter and
CSF tissue compartments using tissue probability maps.
Resulting SPECT images were then intensity normalised
using the occipital lobe as the reference region and
warped into Montreal Neurological Institute (MNI) stand-
ard space. We performed a two-sample t-test (PD vs CTL
group), with age, sex, antidepressant medication and med-
ical centre as covariates. T-maps contrasts were obtained
by comparing groups with family-wise error (FWE)-cor-
rected p < 0.05, limiting the results to the expected cluster
voxel size according to SPM.
ROI-based analyses
Uptake extraction of the significant striatal and extra-
striatal ROIs found in the voxel-wise analysis was per-
formed with PETPVE12 [18] for correlation with clinical
scales. After SPECT/MRI coregistration and MRI seg-
mentation described above, we proceeded to ROI uptake
extraction using geometric transfer matrix (GTM), in-
cluding partial volume effect (PVE) correction. SPECT
images were smoothed using an 8mm full width at half-
maximum (FWHM) Gaussian kernel. The Desikan-
Killiany was used for ROI uptake extraction [19] (Fig. 1).
Semiquantitative values were obtained using the occipi-
tal lobe as the reference (REF) for DAT-rich ROIs (caud-
ate nucleus, putamen and pallidum) or cerebellar grey
matter for SERT-rich regions (amygdala and insula) [20]
using the specific/non-specific binding ratio (SBR) as
SBR = (UptakeROI – UptakeREF)/UptakeREF.
Statistical analysis
Statistical analyses were performed with Stata Version
14.2 software (College Station, TX). Continuous variables
were assessed for normality with plotted histograms and
Shapiro-Wilk test. We used t-test or Mann-Whitney U
test (MWU) for continuous variables with a normal and
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non-normal distribution, respectively. χ2 test was per-
formed for categorical variables.
Correlation analyses were performed for PD using uni-
variate linear regressions between clinical motor/non-
motor scales and ROIs with significantly reduced uptake
in PD. Between-ROI correlations were also performed
using the same covariates. When assessing a correlation
with a motor scale (MDS-UPDRS III), we used age, sex,
antidepressant medication and centre as covariates and
striatal ROIs uptake on the contralateral side to clinically
more affected side according to MDS-UPDRS III latera-
lising items. These included appendicular rigidity, all
items of bradykinesia (finger tapping, hand movements,
pronation-supination movements of hand, toe tapping,
leg agility), postural and kinetic tremor of hands. Axial
items included speech, facial expression, rigidity of the
neck, arising from chair, gait, freezing of gait, postural
stability and posture.
For non-motor scales (GDS, MoCA, SCOPA sub-
scores, ESS and RBDSQ), MDS-UPDRS III score was
added as an additional covariate to adjust for motor se-
verity and the mean (average of left and right) ROI up-
take was used as the independent variable.
Results
Patients demographics
According to our inclusion criteria (subjects aged ≥40
years, available SPECT and MPRAGE MRI performed
within 3 months interval), 158 early PD and 63 CTL
from 12 different medical centres were eligible for the
present work. During the image preprocessing, 4 PD and
1 CTL subjects were excluded because of technical is-
sues related to SPECT/MRI coregistration. Eventually,
154 PD and 62 CTL were included for group compari-
sons. Demographics and inclusion flowchart are avail-
able in Table 1 and Fig. 2. Relative to Controls, PD
patients had significantly higher scores for MDS-UPDRS
III (including total score as well as axial and lateralising
items subscores, all p < 0.0001, MWU), Hoehn and Yahr
scale (p < 0.0001, Chi-Squared test), RBDSQ (p < 0.001,
MWU), and SCOPA-AUT (incl. Total score, SCOPA-GI
and SCOPA-URO subscores, all p < 0.05, MWU). No sig-
nificant differences for depression (as measured with
GDS), cognition (MOCA) and excessive daytime sleepi-
ness (ESS) were observed (all p > 0.18, MWU).
Voxel-based 123I-FP-CIT SPECT analyses
Compared to the CTL group, PD subjects showed de-
creased uptake in a first cluster (total 1109 voxels (vx),
peak level T-score 16.3) including right insula, putamen,
amygdala and pallidum. The second cluster (total 1195
vx, peak level T-score 14.4) included left insula, putamen
and caudate nucleus and amygdala. A third smaller clus-
ter (140 vx, peak level T-score 7.4) included right caud-
ate nucleus (all FWE-corrected p < 0.05) (Fig. 3).
Correlation analysis of clinical scales and ROIs 123I-FP-CIT
uptake
ROI-based uptake values of striatal (caudate nucleus and
putamen) and extrastriatal (pallidum, insula and amyg-
dala) regions of interest are available in Table 2. Strong
correlations were observed between caudate nucleus, pu-
tamen and pallidum 123I-FP-CIT uptake (all p < 0.001),
while insula binding correlated with caudate nucleus and
putamen binding (both p < 0.001) but not with pallidum
(p = 0.83). Uptake in the amydala correlated with putamen
(p = 0.004) and insula (p < 0.001), but not with caudate nu-
cleus (p = 0.14) or pallidum (p = 0.20). Similar findings
were observed when studying the subgroup of PD patients
with GDS ≥ 5. However, when assessing only PD patients
with mild cognitive impairment (MOCA ≤25, n = 30), we
did not observe any significant correlation between striatal
Fig. 1 Regions of interest used for the present study, extracted with the Desikan-Killiany atlas: (left) cerebellum grey matter (magenta), (center)
amygdala (cyan), (right) caudate nucleus (blue), putamen (red), pallidum (green), insula (white) and occipital lobe grey matter (yellow). Numbers
represent Z-axis coordinates in Montreal Neurological Institute space
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and extrastriatal, except for a trend association between
putamen and amygdala 123I-FP-CIT binding (p = 0.09).
Higher MDS-UPDRS III was associated with lower
123I-FP-CIT uptake in the putamen contralateral to clin-
ically more affected side (p = 0.022, coefficient = − 9.2,
95% confidence interval (CI) -17 to − 1.4). No significant
correlation was found between ROIs uptake and MoCA
(all p > 0.45). We found a trend association between
higher GDS and lower mean 123I-FP-CIT pallidal uptake
(p = 0.08, coefficient − 0.65, 95% CI − 1.39 to 0.09).
Higher SCOPA-GI correlated with lower mean putamen
(p = 0.01, coefficient − 2.2, 95% CI − 3.9 to − 0.5) and
Table 1 Demographics for the PD and CTL groups
PD (n = 154) CTL (n = 62) p-value
Age (years) 61.6 ± 8.9 (40–82) 61.5 ± 10 (40–81) 0.87 §
Male distribution 61.7% (98/154) 61.5% (41/62) 0.73 #
Right-handedness 90.3% (139/154) 82.3% (51/62) 0.19 #
Disease duration (months) 25.5 ± 17.8 (2–77) NA –
MDS-UPDRS III at baseline 22.3 ± 9.7 (5–46) 0.5 ± 1.2 (0–8) < 0.0001 §
MDS-UPDRS III axial subscore 4.0 ± 2.6 (0–12) 0.1 ± 0.3 (0–2) < 0.0001 §
MDS-UPDRS III right-sided items subscore 7.9 ± 4.8 (0–20) 0.2 ± 0.5 (0–3) < 0.0001 §
MDS-UPDRS III left-sided items subscore 7.7 ± 6.1 (0–23) 0.3 ± 0.6 (0–3) < 0.0001 §
Hoehn-Yahr scale 1.5 ± 0.5 (1–2) 0 (0–0) < 0.001 #
MOCA 27.4 ± 2.2 (20–30) 28.2 ± 1.2 (26–30) 0.19 §
GDS 5.3 ± 1.4 (1–11) 5.1 ± 1.2 (3–10) 0.39 §
SCOPA-AUT 10.5 ± 6.0 (0–40) 7.5 ± 4.5 (0–19) 0.0002 §
SCOPA-AUT Gastrointestinal subscore 2.3 ± 1.9 (0–11) 0.8 ± 1.0 (0–4) < 0.0001 §
SCOPA-AUT Urological subscore 3.9 ± 2.5 (0–14) 3.2 ± 2.3 (0–12) 0.03 §
Epworth Sleepiness Scale 6.2 ± 4.0 (0–19) 5.9 ± 3.3 (0–15) 0.68 §
REM-sleep behavior disorder screening questionnaire 4.3 ± 2.6 (1–12) 2.9 ± 2.2 (0–10) < 0.001 §
Baseline demographics of PD and CTL subjects included in the study. Statistical tests: Chi-square #, Mann-Whitney U test §. NA not applicable
Fig. 2 inclusion process of the study
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caudate nucleus uptake (p= 0.034, coefficient − 1.48, 95% CI
− 2.9 to − 0.1). Finally, higher SCOPA_URO subscore was
associated with lower mean uptake in the caudate nucleus
(p= 0.002, coefficient − 2.7, 95% CI − 4.3 to − 1.0), putamen
(p= 0.013, coefficient − 2.7, 95% CI − 4.6 to − 0.6) and palli-
dum (p= 0.025, coefficient − 1.4, 95% CI − 2.7 to − 0.2).
No significant correlation was observed between ESS
and ROIs 123I-FP-CIT uptake (all p > 0.29). However, we
observed that – among PD participants – higher RBDSQ
was associated with lower 123I-FP-CIT uptake in caudate
nucleus, putamen and pallidum (all p < 0.05). All correla-
tions are available in Table 3.
Regarding antidepressant medication, we observed that
PD patients on SSRI/SNRI treatment had non-significantly
lower 123I-FP-CIT uptake values in caudate nucleus, puta-
men, pallidum and insula compared to patients without
antidepressants (4–8% reduction, all p > 0.11, MWU). Con-
versely, 123I-FP-CIT binding in the amygdala was slightly
higher in patients on SSRI medication (9% increase, p =
0.10, MWU). SSRI/SNRI treatment was added as a
dichotomised variable in the regression analyses and did
not show any significant effect on striatal or extrastriatal
uptake (all p > 0.10).
Discussion
In the present work, we showed that in addition to a
well-known decrease in 123I-FP-CIT uptake involving
the striatum, early PD subjects exhibit a significant up-
take reduction in extrastriatal regions including the palli-
dum, amygdala and insula. As extrastriatal 123I-FP-CIT
binding mainly derives from SERT [2], we took advan-
tage of the same scanning session of a large PD cohort
to confirm early binding changes in regions outside the
striatum compared to similarly-aged Controls.
123I-FP-CIT impairment in pallidum was recently ob-
served by Lee et al. [21]. 11C-PE2I and 11C-DASB PET
studies showed that while the lateral part of the pallidum
(globus pallidum externus) has a similar proportion of sero-
tonergic and dopaminergic terminals, the medial part (glo-
bus pallidus internus) is mainly a serotonergic nucleus [20].
In addition, our PD subjects exhibited an impaired extra-
striatal uptake in the insula and amygdala. These findings
confirm recent data by Pilotto et al. showing decreased
123I-FP-CIT uptake in insula, thalamus and cingulate in
both PD and dementia with Lewy bodies [9]. Moreover,
they confirm previous neuropathological evidence and
in vivo 11C-DASB-PET and 123I-FP-CIT SPECT studies
showing an altered serotonergic uptake for PD in the insula
[6, 8], providing additional value for 123I-FP-CIT SPECT, a
major diagnostic imaging tool in daily clinical practice.
Findings of a reduced 123I-FP-CIT uptake in the amygdala
are also in line with post-mortem studies using chromatog-
raphy and enzyme-linked immunosorbent assay showing
Fig. 3 Axial and coronal slices of voxel-wise 123I-FP-CIT SPECT group comparisons between CTL and PD subjects. Cluster #1 (left, center and right)
includes right insula, putamen, amygdala and pallidum, Cluster #2 (left, center and right) includes left insula, putamen and caudate nucleus and
amygdala, Cluster #3 (center) includes right caudate nucleus (FWE-corrected p < 0.05). Color bar represents T-score. R = right. Numbers are Z-axis
coordinates in MNI space
Table 2 Regional 123I-FP-CIT uptake values for the PD and
Control groups
PD (n = 154) Controls (n = 62) pval
Caudate nucleus 2.66 ± 0.95 3.60 ± 1.03 < 0.0001
Putamen 1.34 ± 0.46 2.54 ± 0.44 < 0.0001
Pallidum 1.51 ± 0.80 2.56 ± 0.56 < 0.0001
Insula 0.43 ± 0.16 0.64 ± 0.19 < 0.0001
Amygdala 0.52 ± 0.21 0.59 ± 0.19 0.01
Average (mean of left and right) 123I-FP-CIT uptake values for PD and Control
groups for striatal and extrastriatal regions-of-interest. For comparative
purposes, the same reference region (occipital lobe) was used for the present
results. All group comparisons are performed using Mann-Whitney U test
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that PD subjects had reduced dopamine and noradrenaline
levels in the amygdala [22].
Our correlation analysis confirmed that motor impair-
ment as measured by MDS-UPDRS III total score was
associated with decreased putaminal 123I-FP-CIT uptake
[23]. It might seem surprising that MDS-UPDRS III was
not more strongly correlated with striatal ROIs 123I-FP-
CIT uptake. However, a recent psychometric assessment
of MDS-UPDRS part II and III scales in PD subjects en-
rolled into the PPMI cohort showed an important floor
effect, which can explain the moderate association for
our cohort [24].
Clinical association with an extensive serotonergic deficit
may include apathy, emotional disturbances, depression,
Table 3 Correlations between clinical motor and non-motor scales and regional 123I-FP-CIT uptake in PD
Score Region of interest Coefficient pval 95% Confidence Interval
MDS-UPDRS III PUT* −9.2 0.022 [− 17; − 1.4]
CN* −4.4 0.44 [− 15.6; 6.8]
PAL* −1.46 0.67 [−8.1; 5.2]
INS − 3.4 0.22 [−8.9; 2.0]
AMYG −1.8 0.25 [−4.8; 1.2]
MOCA PUT −0.47 0.62 [−2.3; 1.4]
CN −0.26 0.74 [−1.8; 1.3]
PAL −0.1 0.85 [−1.2; 1]
INS −0.02 0.97 [−1.3; 1.2]
AMYG −0.26 0.46 [−1; 0.4]
GDS PUT 0.54 0.39 [−0.7; 1.8]
CN −0.30 0.56 [−1.3; 0.7]
PAL −0.65 0.08 [−1.4; 0.1]
INS 0.51 0.22 [−0.3; 1.3]
AMYG −0.13 0.59 [−0.6; 1.3]
SCOPA-GI PUT −2.2 0.01 [−3.9; −0.5]
CN −1.48 0.034 [−2.9; −0.1]
PAL −0.06 0.90 [−1.1; 1]
INS −0.66 0.25 [−1.8; 0.5]
AMYG −0.2 0.54 [−0.8; 0.4]
SCOPA-URO PUT −2.7 0.013 [−4.6; −0.6]
CN −2.7 0.002 [−4.3; −1.0]
PAL −1.4 0.025 [−2.7; −0.2]
INS −0.66 0.36 [−2.1; 0.75]
AMYG −0.44 0.27 [−1.2; 0.4]
ESS PUT −0.79 0.63 [−4; 2.4]
CN −0.33 0.81 [−3.1; 2.4]
PAL −0.99 0.30 [−2.9; 0.9]
INS 0.25 0.81 [−1.8; 2.3]
AMYG 0.01 0.99 [−1.1; 1.1]
RBDSQ PUT −3.27 0.010 [−5.7; −0.8]
CN −2.35 0.028 [−4.4; − 0.3]
PAL −1.56 0.036 [−3.0; −0.1]
INS −0.08 0.92 [−1.7; 1.54]
AMYG 0.37 0.40 [−0.52; 1.27]
Correlations between clinical scores and 123I-FP-CIT ROIs uptake. All uptake values are average (mean of left and right), except * = contralateral side to clinically
more affected side. PUT putamen, CN caudate nucleus, PAL pallidum, INS insula, AMYG amygdala. Significant results are highlighted in bold
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cognitive deficits, and dysautonomic manifestations in PD,
all of which being potentially present early in the disease
course or even in its prodromal phase [25].
Previous studies did not show any significant correlation
between striatal 123I-FP-CIT binding and non-motor
symptoms such as fatigue, depression and excessive day-
time sleepiness in PD [26]. Using a ROI-based approach
to assess the contribution of extrastriatal ROIs, Qamhawi
et al. observed a reduced 123I-FP-CIT binding in the raphe
nucleus in early PD patients from the PPMI initiative
compared to Controls (although only 12.5% of PD had
values below 1.5 standard deviation). They also found that
raphe nucleus binding was associated with rest tremor
amplitude, constancy and severity, but not with non-
motor symptoms such as depression, REM-sleep behav-
iour disorder and excessive daytime sleepiness [27].
While a trend association was found between GDS
and pallidal 123I-FP-CIT uptake in the present study, we
did not find a significant correlation between SERT-rich
regional uptake and cognitive impairment as measured
with MOCA. One reason might be that other monoam-
inergic pathways are involved in the pathophysiology of
cognitive impairment [23] and that larger samples would
be necessary to tackle such complex processes. In
addition, our PD cohort mainly consisted of early sub-
jects with relatively preserved cognition (mean MoCA
27.4), so admittedly, a significant correlation between
SERT binding and depression/cognitive scales could
have been observed in cohorts with a broader range of
impairment [28].
Interestingly, correlations between striatal and extra-
striatal regions binding among PD patients showed that
caudate nucleus and putamen 123I-FP-CIT uptake im-
pairment was associated with concomitant reductions in
insula and amygdala binding in the full cohort analyses
and also in the PD subgroup with GDS ≥ 5. However,
when assessing these potential associations in the sub-
group with mild cognitive impairment (MOCA ≤25, n =
30), we did not observe such correlations, except for a
trend association between putamen and amygdala up-
take (p = 0.09). The smaller subgroup could explain the
lack of significant association. In addition, changes in
striatal and extrastriatal binding can be of a different
magnitude in patients with cognitive impairment, al-
though we did not find any significant relationship be-
tween extrastriatal binding and cognitive impairment.
Our early PD group did not show any major signs of
excessive daytime sleepiness, with ESS scores similar to
Controls (p = 0.68). At variance with Yousaf et al. [29], no
significant correlation between ESS and striatal 123I-FP-
CIT uptake was observed in PD (all p > 0.29). Differences
in the inclusion criteria could explain the apparently op-
posite findings. In fact, Yousaf et al. [29] performed
between-group comparisons of PD with or without
excessive daytime sleepiness, whereas we assessed correla-
tions with striatal/extrastriatal 123I-FP-CIT using a cohort
with relatively low ESS score.
In contrast, we observed that PD group had a signifi-
cantly increased RBDSQ score (p < 0.001) relative to
Controls, with 51/154 PD (33.1%) having RBDSQ ≥5.
Moreover, higher RBDSQ was associated with lower
123I-FP-CIT binding in caudate nucleus, putamen and
pallidum (all p < 0.05). These findings are in line with
Pagano et al., who showed that RBD was associated with
faster striatal dopaminergic decline [30].
Finally, a significant association was found between
SCOPA-GI subscore and caudate/putamen uptake. This
confirms previous observations from Hinkle et al. [31],
who described an association between SCOPA-GI score
(especially constipation items) and both regions. Add-
itionally, we observed that the SCOPA-URO subscore
was also negatively correlated with striatal uptake. This
is in line with previous findings from Kim et al. [32] who
recently found a correlation between putamen uptake
and SCOPA-URO subscore also including the PPMI co-
hort. For both studies from Hinkle and Kim, SPECT/
MRI coregistration was not performed. While our find-
ings are of interest, they should be interpreted with an
important caveat in mind. In fact, while bowel motility
in late-life has been associated with postmortem neuron
density in the substantia nigra [33], a causal relationship
between presynaptic striatal dopamine uptake and
gastrointestinal impairment in early PD would be hasty.
Indeed, one hypothesis would be that dysautonomia
would appear concurrently to striatal dopaminergic de-
generation and not necessarily be driven by it.
Studies on rats and humans have shown conflicting re-
sults regarding the effect of antidepressant medication
(SSRI/SNRI) on 123I-FP-CIT uptake values. In rats, sub-
chronic administration of fluvoxamine was not associated
with significant changes in striatal 123I-FP-CIT uptake
[34]. In humans, higher binding in striatal regions and
lower binding in extrastriatal regions was observed after
acute treatment of paroxetine [35], while chronic treat-
ment was associated with lower striatal binding [36],
which is in line with our findings.
The present study has several major strengths: first, it
is based on a large cohort of well-characterized PD and
CTL subjects who underwent extensive clinical motor
and non-motor evaluation. In addition, we included sub-
jects whose SPECT was acquired within 3 months of a
high-resolution anatomical MRI in order to proceed to
MRI/SPECT coregistration and to provide PVE-corrected
results. Although our included subjects represent about
half of the total PD subjects in the PPMI cohort, given the
stringent inclusion criteria we applied for analyses pur-
poses, we believe this provides a major insight into the
pathophysiology of monoaminergic degeneration in PD.
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The present work also presents some limitations. As this
is the case in similar clinical studies, diagnoses are not
based on neuropathology, so we cannot exclude diagnostic
misattribution, especially since some PD cases were en-
rolled at a very early stage (10 subjects with < 6-month
disease duration). In addition, SPECT acquisition was per-
formed 3-4 h after 123I-FP CIT injection, which is the ideal
timeframe for DAT evaluation, whereas the recommended
time window for extrastriatal SERT is 2-3 h [2]. Nonethe-
less, due to a slow 123I-FP-CIT washout, we expect SERT
binding to be relatively stable at 3-4 h [37].
Conclusion
We presented evidence of a widespread 123I-FP-CIT
extrastriatal impairment in early PD, spanning the amyg-
dala and insular region, which is in keeping with neuro-
pathological and 11C-DASB PET imaging. As 123I-FP-
CIT SPECT imaging is used daily to confirm nigrostria-
tal degeneration, these results bring novel evidence for a
potential role in helping to discriminate PD from non-
degenerative conditions by assessing extrastriatal uptake.
Further studies are warranted to assess whether atypical
parkinsonian syndromes harbour similar extrastriatal
123I-FP-CIT impairment, therefore confirming complex




nortropane; SPECT: Single photon emission computed tomography;
SERT: Serotonin transporter; 11C-DASB: 11C-3-amino-4-(2-
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